Navigation Links
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Date:5/14/2008

ard of care regimen for each genotype. Preliminary safety and antiviral activity data from the 4-week combination treatment period are anticipated during the third quarter of 2008.

"Based on our pharmacokinetic modeling, we believe that the R7128 1000mg BID combination dosing regimen in Cohort 3 may be able to achieve similar antiviral responses as were demonstrated with R7128 1500mg BID in Cohort 2," stated Dr. Michelle Berrey, Pharmasset's Chief Medical Officer. "Cohort 4 will be the first administration of R7128 in patients with HCV genotypes 2 or 3, and thus will serve as proof-of-concept for this population who we believe represent an area of great unmet medical need. If R7128 shows activity in HCV genotype 2 or 3 patients, this would demonstrate a distinct clinical attribute of nucleoside polymerase inhibitors."

Please see http://www.clinicaltrials.gov or e-mail clinicaltrials@pharmasset.com for more information.

About R7128

R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. Results from a Phase 1 oral single ascending dose study of R7128 in 46 healthy male volunteers showed that R7128 was generally well tolerated with no serious adverse events in doses up to 9000 mg.

In a Phase 1 study, R7128 demonstrated potent, dose-dependent antiviral activity across four genotype 1 prior treatment-failure patient cohorts (n=40) receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. The greatest mean decrease in HCV RNA from baseline was demonstrated in the patient cohort that received 1500 mg twice-daily, the highest dose of R7128 administered in the study. These patients demonstra
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
10. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... FRANKFURT AM MAIN, Germany , ... Risk App from Merz Pharmaceuticals is available free of charge ... risk for getting dementia within the next two decades. Using ... physicians discuss preventive measures with patients at risk. ... and Incidence of DEmentia) has been developed in collaboration with ...
(Date:8/27/2014)... China, Aug. 28, 2014 China Nepstar ... or the "Company"), a leading retail drugstore chain ... operated stores, today announced its unaudited financial results ... Financial HighlightsFor the quarter ended June 30, 2014: ... million (US$110.7 million) compared to RMB638.8 million in the ...
(Date:8/27/2014)... VANCOUVER, British Columbia and MENLO ... DelMar Pharmaceuticals, Inc. , (OTCQB: DMPI), developer of ... presenting company at the 16th Annual Rodman & Renshaw ... & Co., LLC. The presentation will take place Tuesday, September ... Salon (4th floor) at the New York Palace Hotel ...
Breaking Medicine Technology:CAIDE Looks into the Future: New App from Merz Pharmaceuticals Assesses the Risk of Getting Dementia Within the Next 20 Years 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4
... (Nasdaq: PRGO ; TASE) today announced that it ... foam brought by Stiefel Research Australia Pty. Ltd., a GSK ... in the U. S., a generic version of Men,s Rogaine® ... Rogaine® (Minoxidil) Foam is used to regrow ...
... Informex , the leading meeting place for buyers ... applications, today announced details of its second Latin American Green ... The event will be held in September 2011, with further ... 2011 event follows the success of the inaugural Informex Latin ...
Cached Medicine Technology:Perrigo Announces Settlement of Rogaine® Foam Patent Litigation 2Second Annual Latin America 'Green Exchange Conference' Hosted by Informex Focuses on a Sustainable Future for Chemistry 2Second Annual Latin America 'Green Exchange Conference' Hosted by Informex Focuses on a Sustainable Future for Chemistry 3
(Date:8/28/2014)... 28, 2014 In the healthcare industry, ... practices struggle with: How can the overall quality of ... study of the healthcare industry tackles this question, and ... employee job satisfaction and the quality of patient care. ... found in “ Organizational Factors related to Improving Quality ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 DoctorBase ... and mid-sized healthcare organizations, today announced that it has ... appointment company ZocDoc , to head their sales ... has created a sales management position. , “I’m passionate ... like DoctorBase that already has so much traction and ...
(Date:8/28/2014)... York (PRWEB) August 28, 2014 An unprecedented ... and neck issues, Cloud 9 Spine offers their resources online ... problems can quickly become a brick wall of discouragement as ... a professional opinion, Cloud 9 Spine offers a ... technology merged with human interaction that sets Cloud 9 Spine ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Top ... many web hosting companies and announces Bluehost, HostMonster ... recommended suppliers for the webmasters worldwide who want ... rates. , As the world’s most popular server-side ... and many other general-purpose programs. It is now ...
(Date:8/28/2014)... Now in its 4th year, Step for ... by two brain aneurysm survivors. The ongoing mission of Step ... to help increase early detection and to help support individuals ... We hope that you will be able to join this ... Annual Step for Hope Run/ Walk on Saturday, September 6, ...
Breaking Medicine News(10 mins):Health News:New Healthcare Study Explores Strategies for Improving Patient Care 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 3Health News:New Healthcare Study Explores Strategies for Improving Patient Care 4Health News:DoctorBase Hires Josh Angeles as Vice-President of Sales 2Health News:Making Waves on the East Coast, Cloud 9 Spine is Helping Patients Find Appointments With Local Spine Doctors 2Health News:Step for Hope and Raise Brain Aneurysm Awareness 2
... arise sporadically, rather than through inheritance of certain genes, ... allow environmentally triggered mutations to accumulate, according to researchers ... Hospital of UPMC and the University of Pittsburgh Cancer ... online edition of the Proceedings of the National ...
... the emergence of an epidemic of obesity and type 2 ... that may affect the risk of metabolic diseases is especially ... tend to have about 30% lower risk of developing late ... to be at lower risk of developing metabolic syndrome ...
... Reporter , MONDAY, Nov. 29 (HealthDay News) -- The prescription ... study suggests. But one expert was quick to note ... the pain of arthritis, has been linked in some studies ... So it isn,t yet clear that Celebrex (celecoxib) is an ...
... , MONDAY, Nov. 29 (HealthDay News) -- Smoking boosts the ... and those with a genetic risk factor for rheumatoid arthritis ... a new study has found. Researchers evaluated 605 black ... found that those with the disease were slightly more likely ...
... The American College of Physicians (ACP) today is sending ... internists speaking in their own words ( ... Congress to avert the scheduled Medicare Sustainable Growth Rate ... the repeated cycle of cuts. The 3-minute and ...
... the Psychoimmunology Unit at Lund University is presenting these results ... group led by Dr Lena Brundin, which sees inflammation in ... is a new theory that challenges the prevalent view that ... serotonin and noradrenaline. "However, current serotonin-based medication cures far ...
Cached Medicine News:Health News:Sporadic breast cancers start with ineffective DNA repair systems, Pitt researchers find 2Health News:Moderate alcohol consumption lowers the risk of metabolic diseases 2Health News:Celebrex Shows Potential in Preventing Some Skin Cancers: Study 2Health News:Celebrex Shows Potential in Preventing Some Skin Cancers: Study 3Health News:Heavy Smoking May Double Rheumatoid Arthritis Risk in Blacks 2Health News:Internists issue heartfelt plea for Congress to help patients by stopping Medicare SGR cuts 2Health News:Internists issue heartfelt plea for Congress to help patients by stopping Medicare SGR cuts 3Health News:Biological changes in suicidal patients 2
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
85 right angled suture passer....
The Mini-Revo suture anchor is designed primarily for arthroscopic and open Bankart shoulder repair. Additional applications include other shoulder repair procedures, as well as use in small joints....
... Labral Anchor is an L-PLA anchor ... soft tissue reattachment to bone. The ... bony contour of the glenoid, optimizing ... Osteo Compression (ROC) design to provide ...
Medicine Products: